Pegozafermin · ENLIGHTEN-Cirrhosis
This is the compensated-cirrhosis/F4 study, not the separate ENLIGHTEN-Fibrosis F2–F3 trial. Its 24-month fibrosis-regression analysis must be named separately from event-driven clinical outcomes. pegozafermin — phase 3 study in Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis. NCT06419374 lists Proportion of Participants Achieving Fibrosis Regression as a primary outcome (Baseline through Month 24). Registry status: recruiting.
What matters
Track what the company has actually announced, the study or asset involved, and the evidence needed to confirm the milestone.
- Specify the exact future analysis/cohort and verify that it remains unpublished before creating any tradeable question.
- Registry design and recruitment status are not evidence of efficacy or regulatory approval.
- Primary completion is not a guaranteed topline publication or regulatory decision date.
- Registry primary completion: 2028-06-30 (estimated); verify independently before using it as a catalyst date.
- An active study record does not establish that its primary outcome is still unannounced. Review sponsor disclosures before promotion to a future catalyst.
- The registry lists 2 primary outcome measures. A market must explicitly specify which endpoint or conjunction resolves YES; this card highlights one measure only.
Primary evidence
Long-horizon cirrhosis study — date unconfirmed
Potential outcome market
Will pegozafermin meet the prespecified primary endpoint in NCT06419374 by a listing deadline still to be specified?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.